A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.
Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 T cells and the investigators will determine the safety and therapeutic effects of these cells.
⁃ CD19 positive leukemia and lymphoma，relapsed and/or refractory：
• survival\>12 weeks;
• FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
• LVEF≥50%;
• Creatinine\<2.5mg/dl;
• Bilirubin\<2.5mg/dl;
• ALT (alanine aminotransferase)/AST (aspartate aminotransferase)\<3 x normal;
• At least 7 days after last chemotherapy;
• provide with informed consent.